Business
Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track to initiate Phase 1 trials for three
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track to initiate Phase 1 trials for three additional wholly owned drug candidates in 2021 Strong financial position with $496 million as of May 31, 2021 SAN FRANCISCO, July 13, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the second quarter ended May 31, 2021 and provided a corporate update. “Our first clinical trial to evaluate NX-2127, an orally bioavailable degrader of Bruton’s tyrosine kinase with immunomodulatory drug activity in patients with relapsed or refractory B-cell malignancies is actively recruiting, and we anticipate sharing preliminary data from the dose escalation by year-end 2021,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “The second half of 2021 promises to be an exciting time for Nurix as we prepare to deliver on our ambitious goal of initiating Phase 1 trials for three additional wholly owned and internally developed drug candidates.” Recent Business Highlights Expanded the Leadership Team with the Addition of a Chief Operating Officer: Nurix announced the appointment of Stefani A. Wolff as chief operating officer and executive vice president of product development. Ms. Wolff brings to Nurix over 30 years of leadership experience in oncology and immunology most recently from Principia Biopharma Inc., where she served as chief development officer and formerly senior vice president of strategy and operations overseeing Principia’s portfolio including Bruton’s tyrosine kinase (BTK) targeted agents.Strengthened the Board of Directors with a Highly Successful Biotechnology Executive: Nurix announced the appointment of Clay Siegall, Ph.D., president, chief executive officer and chairman of Seagen (formerly Seattle Genetics, Inc.), to its board of directors. Dr. Siegall is an industry leader with a remarkable track record of success in building Seagen from a drug discovery platform company to a commercial-stage oncology company with multiple products. Dr. Siegall co-founded Seagen in 1998, which today has three FDA-approved medicines and is an industry leader in antibody-drug conjugate technology and development.Presented Preclinical D...